Carlsmed, Inc. (NASDAQ:CARL) Sees Significant Growth in Short Interest

Carlsmed, Inc. (NASDAQ:CARL) was the target of a large growth in short interest in the month of September. As of September 30th, there was short interest totaling 744,800 shares, a growth of 48.0% from the September 15th total of 503,100 shares. Based on an average daily volume of 213,100 shares, the days-to-cover ratio is presently 3.5 days. Approximately 7.7% of the shares of the stock are sold short. Approximately 7.7% of the shares of the stock are sold short. Based on an average daily volume of 213,100 shares, the days-to-cover ratio is presently 3.5 days.

Carlsmed Stock Performance

Shares of CARL stock opened at $13.01 on Friday. Carlsmed has a twelve month low of $11.81 and a twelve month high of $16.20.

Carlsmed (NASDAQ:CARL) last issued its quarterly earnings results on Thursday, August 28th. The company reported ($1.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.52) by $0.05. The firm had revenue of $12.08 million during the quarter, compared to analyst estimates of $11.98 million.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings initiated coverage on Carlsmed in a report on Thursday, October 16th. They set a “sell (e)” rating on the stock. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Carlsmed Company Profile

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).